- Home
- WRLD vs RCUS Comparison
WRLD vs RCUS Comparison
Compare WRLD & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRLD
- RCUS
- Stock Information
- Founded
- WRLD 1962
- RCUS 2015
- Country
- WRLD United States
- RCUS United States
- Employees
- WRLD N/A
- RCUS N/A
- Industry
- WRLD Finance: Consumer Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- WRLD Finance
- RCUS Health Care
- Exchange
- WRLD Nasdaq
- RCUS Nasdaq
- Market Cap
- WRLD 727.3M
- RCUS 727.1M
- IPO Year
- WRLD 1991
- RCUS 2018
- Fundamental
- Price
- WRLD $140.55
- RCUS $8.28
- Analyst Decision
- WRLD
- RCUS Buy
- Analyst Count
- WRLD 0
- RCUS 11
- Target Price
- WRLD N/A
- RCUS $25.33
- AVG Volume (30 Days)
- WRLD 26.9K
- RCUS 1.2M
- Earning Date
- WRLD 04-29-2025
- RCUS 05-06-2025
- Dividend Yield
- WRLD N/A
- RCUS N/A
- EPS Growth
- WRLD 23.55
- RCUS N/A
- EPS
- WRLD 16.30
- RCUS N/A
- Revenue
- WRLD $564,842,000.00
- RCUS $141,000,000.00
- Revenue This Year
- WRLD $0.79
- RCUS N/A
- Revenue Next Year
- WRLD $2.18
- RCUS $25.77
- P/E Ratio
- WRLD $8.62
- RCUS N/A
- Revenue Growth
- WRLD N/A
- RCUS N/A
- 52 Week Low
- WRLD $101.85
- RCUS $6.50
- 52 Week High
- WRLD $161.63
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- WRLD 61.31
- RCUS 48.63
- Support Level
- WRLD $129.79
- RCUS $7.06
- Resistance Level
- WRLD $134.45
- RCUS $9.35
- Average True Range (ATR)
- WRLD 5.56
- RCUS 0.55
- MACD
- WRLD 0.76
- RCUS 0.06
- Stochastic Oscillator
- WRLD 75.33
- RCUS 53.28
About WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.